PSS4 A Cost Effectiveness Analysis of Latanoprost Monotherapy, Netarsudil Monotherapy and Fixed Dose Combination Latanoprost/Netarsudil in Management of Primary Open Angle Glaucoma in USA

Netarsudil and recently approved fixed dose combination (FDC) Netarsudil/Latanoprost have shown significant effect of lowering intra-ocular pressure in glaucoma comparable to most widely used prostaglandin analog, Latanoprost. This research aims to assess the cost-effectiveness of FDC Netarsudil/Latanoprost, monotherapy Netarsudil 0.02% and monotherapy Latanoprost 0.005% in reducing intra-ocular pressure (IOP).
Source: Value in Health - Category: International Medicine & Public Health Authors: Tags: Sensory System Disorders - Economic Evaluation Source Type: research